Warning Letter — BioMylz Pvt. Ltd.
The FDA issued a Warning Letter to BioMylz Pvt. Ltd. following an evaluation by the Center for Drug Evaluation and Research (CDER).
This notice affects BioMylz Pvt. Ltd., specifically their personnel involved in drug manufacturing, quality assurance, and regulatory compliance.
The issuance of a Warning Letter by CDER signifies that the firm has demonstrated significant violations of Current Good Manufacturing Practice (CGMP) regulations. This may lead to the withholding of new product approvals or the refusal of admission of products into the United States until the violations are corrected and verified by the FDA.
Regulatory and QA teams should conduct a thorough audit of manufacturing facilities to ensure alignment with CGMP standards. Any identified gaps in production or quality control documentation should be addressed through a formal CAPA process before further shipments to the U.S. market.
FDA Warning Letter issued to: BioMylz Pvt. Ltd.. 07/13/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/biomylz-pvt-ltd-729483-07132026
Open in openFDA / FDA.gov